Corgentech cardiovascular news

CGTK restructured and will reduce its headcount by 45% to about 70 employees. The move follows last month's decision to discontinue development of E2F Decoy edifoligide after the compound failed its second Phase III trial to prevent graft failure following surgical procedures.

After edifoligide, CGTK's most advanced program is NF-kappaB Decoy. In Jan., CGTK submitted an IND to begin a Phase I/II trial of the selective potent inhibitor of transcription factor NF-kappaB to treat eczema. The compound also is in preclinical development to treat inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). ...